Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Twist Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Twist Bioscience's regulatory disclosures and financial reporting.
On August 3, 2026, Paula Green, SVP of Human Resources at Twist Bioscience Corp, sold 1,133 shares of common stock at an average price of $85.3212 per share.
A footnote states these shares were sold under a mandated "sell to cover" arrangement to satisfy tax withholding on vesting Restricted Stock Units and did not represent discretionary trades. Following the sale, she directly holds 119,281 shares.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 5,101 shares of Common Stock on 2026-08-03 at an average price of $85.3212 per share. According to the disclosure, these shares were sold to cover tax withholding obligations upon vesting of Restricted Stock Units under the company’s equity incentive plans and "do not represent discretionary trades." Following this transaction, Leproust directly holds 818,938 shares of Common Stock and maintains various employee stock options with specified vesting schedules, including performance stock options exercisable at $67.85 per share on 64,950 underlying shares that vested after meeting performance criteria.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, sold 167 shares of common stock on 2026-08-03 at $85.3212 per share. According to the company’s equity incentive plans, this mandated “sell to cover” transaction funded tax withholding on vesting Restricted Stock Units and was not discretionary. Following the sale, Werner directly held 46,160 shares.
Twist Bioscience Corp officer Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary, reported a sale of 1,070 shares of common stock on 2026-08-03 at $85.3212 per share. According to the footnote, this mandated "sell to cover" transaction funded tax withholding on vesting Restricted Stock Units and was not a discretionary trade. After the sale, Cho directly held 104,071 shares of common stock.
Dennis H. Cho filed a notice to sell 14,205 shares of TWST common stock through Fidelity Brokerage Services LLC. The planned sale has an aggregate market value of $1,558,998.75, with 62,707,424 shares outstanding and an approximate sale date of August 5, 2026 on NASDAQ.
The disclosure also lists prior sales of TWST common stock during the past three months by Dennis H. Cho, including transactions of 14,205 shares for $990,798.75 on May 29, 2026 and 14,205 shares for $1,274,898.75 on June 24, 2026, plus several smaller sales.
Twist Bioscience Corporation is offering $250.0 million of shares of its common stock in a primary underwritten offering, with an option for underwriters to purchase up to an additional $37.5 million of common stock for 30 days. The stock trades on the Nasdaq Global Select Market under the symbol TWST.
Twist expects to use the net proceeds, together with existing cash, cash equivalents and short-term investments, to fund research and development, expand manufacturing capacity and product offerings, and for working capital and other general corporate purposes, with potential in-licensing or acquisitions. As of June 30, 2026, net tangible book value was $350.8 million, or $5.60 per share, based on 62,674,150 shares outstanding. For the quarter ended June 30, 2026, revenue was $118.4 million, with a net loss of $35.1 million and adjusted EBITDA of $(11.3) million.
Twist Bioscience reported strong top-line growth for the quarter ended June 30, 2026, with revenue up 23.2% to $118.4 million and nine‑month revenue up 20% to $332.8 million, driven by both DNA synthesis and protein solutions and NGS applications. Revenue rose across all regions and industries, and genes shipped grew 56% in the quarter to 369,000.
Profitability remains challenging. Gross margin was 52.8% for the quarter and 52.1% year‑to‑date, but the company posted a quarterly net loss of $35.1 million and a nine‑month net loss of $109.6 million, with higher selling, general and administrative expenses and a $7.2 million litigation settlement charge. Operating cash outflow was $41.3 million for the nine months.
Liquidity appears solid, with $166.8 million in cash, cash equivalents and short‑term investments and management expecting this to fund operations for at least 12 months. Twist entered a $33.8 million Invenra platform license and equity investment (mostly paid in stock), set up a $200.0 million at‑the‑market equity program, and reached insurance‑funded settlements in a securities class action (about $17.1 million) and related derivative case (about $1.0 million).
TWST insider Emily M. Leproust filed to sell up to 5,101 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $435,223.44, around August 3, 2026. The shares derive from restricted stock vesting on July 31, 2026 as compensation. The filing notes 62,271,314 shares outstanding. It also lists recent sales in May–June 2026, including 24,282 shares for $1,580,245.85 on May 26, 25,017 shares for $1,633,407.46 on May 27, and 18,880 shares for $1,793,600.00 on June 25.
Twist Bioscience Corporation insider Paula Green filed to potentially sell 1,133 shares of common stock through Fidelity Brokerage Services LLC on August 3, 2026 on the NASDAQ market. These shares are tied to restricted stock vesting on July 31, 2026 as compensation from the issuer.
The filing also lists sales of common stock during the prior three months: 1,116 shares on May 4, 2026 for $63,778.06; 1,399 shares on May 21, 2026 for $74,505.99; 884 shares on June 8, 2026 for $61,742.27; 26,137 shares on June 15, 2026 for $2,134,485.95; and 291 shares on June 22, 2026 for $25,410.82.
Dennis H. Cho filed to sell 1,070 shares of common stock through Fidelity Brokerage Services LLC on or about August 3, 2026. These shares were acquired via restricted stock vesting on July 31, 2026 as compensation. Over the prior three months, Cho reported multiple open-market sales, including 14,205 shares for $990,798.75 on May 29, 2026 and another 14,205 shares for $1,274,898.75 on June 24, 2026.